Stock Analysis

The board appointed Deputy CEO Kasey Kaplan as the next chief executive and managing director. The appointment followed a succession process that considered both internal and external candidates, with the support of an external search adviser.

TheTrusteeof the MME Share Trust has been instructed to buy fully paid ordinary shares on market, up to a total value of $1.5 million. Morgans Financial Limited has been appointed to acquire the shares on the trustee's behalf.

The patient pathway for the erectile dysfunction oral film, covering education, telehealth, pharmacy fulfilment and home delivery, is operating end to end. The company said access is intended for eligible patients through applicable prescribing pathways, including the Special Access Scheme Category B, where approvals …

The company launched GI Navigator, a full microbiome and gut test intended to help practitioners resolve complex gastrointestinal symptoms, on 7 October 2026. More than 400 practitioners have joined the waitlist.

Unaudited quarterly customer revenue rose 12.9% quarter on quarter to $1.210 million and was up 42.4% year on year. Activated licences reached 91,323, and activated annualRecurring Revenuereached $4.514 million, both up 1.2% quarter on quarter.

The company said key technical, procedural and operational steps for Stabl-Im are progressing toward a planned Phase 1 clinical evaluation. A clinical feasibility and plasma enrichment study protocol has been advanced, establishing a framework for an initial healthy volunteer study.

Revenue from continuing operations was $125.6 million, up 6% on the prior corresponding period. Gross profit increased 25% to $46.2 million, and EBITDA rose 34.2% to $12.4 million. Adjusted NPATA was $1.4 million, compared with a loss of $5.4 million in the prior period.